# SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer

> **NCT00361244** · PHASE1,PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 6 (actual)

## Conditions studied

- Colorectal Carcinoma

## Interventions

- **DRUG:** SU011248
- **DRUG:** Irinotecan
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00361244
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2007-10
- **Final completion:** 2010-08
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2017-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00361244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00361244, "SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00361244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*